C. Alcon

发表

Cell-line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations

A. Letai, J. Baselga, R. Albert, 2020, bioRxiv.

Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

A. Letai, J. Baselga, R. Albert, 2021, Cancer Research.

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia

J. Samitier, J. Montero, C. Alcon, 2021, Frontiers in Cell and Developmental Biology.

l-Serine dietary supplementation is associated with clinical improvement of loss-of-function GRIN2B-related pediatric encephalopathy

F. Ciruela, B. Colsch, À. Bayés, 2019, Science Signaling.

RETRACTED: Rett-like Severe Encephalopathy Caused by a De Novo GRIN2B Mutation Is Attenuated by D-serine Dietary Supplement

F. Ciruela, À. Bayés, J. Armstrong, 2018, Biological Psychiatry.

ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins

A. Letai, R. Albert, J. Samitier, 2021, Cells.

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment

A. Villanueva, J. Montero, C. Alcon, 2022, Cell death discovery.

Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

J. Mora, J. Samitier, A. Villanueva, 2020, Cell Death & Disease.

A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies

J. Montero, C. Alcon, Albert Manzano-Muñoz, 2019, Clinical Cancer Research.

Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer

C. Alcon, F. Laguia, N. Jiménez, 2024, Frontiers in Pharmacology.